Johnson & Johnson Fujifilm Biologics Facility Investment

United States

Deal value: $2,000,000,000

Johnson & Johnson invested $2 billion in Fujifilm Diosynth Biotechnologies’ new biologics manufacturing facility in Holly Springs, North Carolina, supporting advanced cell culture and fill-finish operations.

Johnson & Johnson's $2 billion equity investment in Fujifilm Diosynth Biotechnologies’ Holly Springs facility is driven by the need to secure advanced biologics manufacturing capacity in the U.S., ensuring supply chain resilience and supporting the production of transformational medicines. The timing reflects strategic responses to rising domestic demand, evolving regulatory incentives, and the desire to mitigate risks from global trade disruptions and tariffs. The fundamental belief is that robust, local manufacturing infrastructure is essential for competitiveness and innovation in biopharma.